Search

Displaying results 1331 - 1340 of 10000 in total
  1. Drug

    Cabotegravir

    go.drugbank.com/drugs/DB11751
    ApprovedInvestigational

    [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

    Products: Vocabria 400 mg/2 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADET, Vocabria 600 mg/3 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADET
  2. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. … ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.

  3. Drug

    VB-201

    go.drugbank.com/drugs/DB15259
    Investigational

    VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).

  4. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers. … [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026]

    Products: KEYTRUDA® 100 MG, KEYTRUDA 100 MG/4 ML IV INFUZYONLUK COZELTI İÇEREN FLAKON, 1 ADET
  5. Drug

    OTL-203

    go.drugbank.com/drugs/DB18643
    Investigational

    OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.

    Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene
  6. Drug

    Coagulation factor VII human

    go.drugbank.com/drugs/DB13150
    ApprovedInvestigational

    Coagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.

    Mixtures: COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETCategories: coagulation factor IX, II, VII and X in combination
  7. Drug

    Sodium fluoride

    go.drugbank.com/drugs/DB09325
    ApprovedInvestigational

    The use of fluoride in dental practice began in the 1940s. … [L4894] Sodium fluoride's benefits on dental health were first observed in the 1930s, when individuals in communities with fluoridated drinking water showed less tooth decay than those without fluoridated

    Mixtures: ADDAMEL N 20 AMPUL, PREVENT 2 EN 1Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. … IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].

    Products: TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET
  9. Drug

    OTX-2002

    go.drugbank.com/drugs/DB17246
    Investigational

    OTX-2002 is a bicistronic messenger ribonucleic acid (mRNA) encoding for ZF-DNMT and ZF-KRAB proteins, encapsulated in a lipid nanoparticle (LNP).

  10. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    [L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval. … [A218721] Several preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form.

    Products: CYSTAGON ® 150 MG, CYSTADROPS® 3.8 MG/ML SOLUCIÓN OFTÁLMICA